Anne-Laure Vallier

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Helena Earl, Louise Hiller, Janet Dunn et al. · The Lancet Oncology · 2015 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Helena Earl, Anne-Laure Vallier, Louise Hiller et al. · The Lancet Oncology · 2013 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

Jean Abraham, Qi Guo, Leila Dorling et al. · Clinical Cancer Research · 2014 · 111 citations

Medicine, Genetics, Oncology +16

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

H. Raza Ali, Aliakbar Dariush, Elena Provenzano et al. · Breast Cancer Research · 2016 · 90 citations · Full text

Medicine, Oncology, Pathology +17

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?

Helena Earl, Elena Provenzano, Jean Abraham et al. · BMC Medicine · 2015 · 54 citations · Full text

Medicine, Oncology, Breast Oncology +16